ISMCS 2024: CardioPace MedTech Showcases World’s Smallest pVAD Clinical Progress and Cutting-Edge MCS Innovations on Global Stage

Nov 22, 2024 20:18 CST Updated 20:18

magAssist

Developer of Extracorporeal Artificial Heart Devices

Source of the article: Yanda Medical Network

The International Society for Mechanical Circulatory Support (ISMCS) is an international academic organization in the field of mechanical circulatory support and cardiac assistance. The conference aims to bring together top experts and scholars from the global artificial heart research and treatment community to discuss and share the latest scientific achievements, technological advancements, and clinical application experiences, striving to provide opportunities to save lives and improve the quality of life for many patients with end-stage heart failure.

November 13-15, 2024The 30th International Society for Mechanical Circulatory Support (ISMCS)Annual Academic ConferenceWas held in Utsunomiya City, Japan.magAssistAs a leading enterprise in the field of heart failure in China, magAssist was invited to participate in this grand event and actively showcased several of its latest research and clinical achievements in the field of mechanical circulatory support. During the academic presentation session, representatives from magAssistProfessor Xu Boshen, Dr. Xu JiahaoThe participants delivered four fascinating keynote reports covering the latest advancements in mechanical circulatory support (MCS) technology, magAssist's R&D philosophy, product insights, and the latest clinical trial results. Among these, Dr. Jiahe Xu served as the moderator for the forum titled "What's new? From Laboratory and Company."

【magAssist Presents at ISMCS with an Excellent Report】

Swipe up and down to view more photos

Minimally Invasive Interventional Artificial Heart NyokAssist(®) pVAD

Efficient Hemodynamic Support System for Safer and More Effective Treatment

▼▼▼

NyokAssist^® pVADIt is an innovative minimally invasive interventional artificial heart, specifically designed to provide cardiovascular hemodynamic support. The device was developed by renowned experts in the field of vascular intervention from Fudan University's Zhongshan Hospital.Academician Ge JunboTeammagAssist Achieves Integrated Innovation Through Medical-Engineering Collaboration, Combining Cutting-Edge Cardiology Technology with Engineering Creativity to Provide Safe and Effective Life Support for Heart Failure Patients and Those Undergoing Complex Cardiac Surgeries.

NyokAssist^®pVAD has multiple technical advantages:

1. With the world's smallest current interventional size of 9Fr, expandable to an operational size of 24Fr, it provides an average flow rate of 3.5L/min and a peak flow rate of 5L/min. The smaller size results in fewer vascular complications.

2. The flexible outflow segment design of the interventional pump enables valve-friendly contact throughout the entire cardiac cycle, reducing the impact of transvalvular interventional pumps on valve motion;

3. NyokAssist® optimizes the pump design based on computational fluid dynamics (CFD) simulation, focusing on hydraulic performance and hemocompatibility. It eliminates low-velocity areas in the flow path, optimizes shear stress distribution, and minimizes residence time. After optimization, the NyokAssist® interventional pump achieves both high hydraulic output and high hemocompatibility.

4. The external motor design avoids the problems of hemolysis and thrombosis caused by heat generation in built-in motors, and significantly reduces the cost of single-use consumables.

Results from animal experiments show that,NyokAssist^® pVADEasy to operate, smooth in arch crossing and valve crossing, and excels in multiple critical physiological indicators such as free hemoglobin, liver and kidney function. This device can effectively enhance the circulatory function of the cardiovascular system, increase mean arterial pressure (MAP), and reduce pulse pressure difference. In terms of hemodynamics, it can effectively decrease left ventricular end-diastolic volume (LVEDV), reduce cardiac workload, and maintain circulatory stability.

In a multicenter randomized controlled trial,NyokAssist^® pVADCompared with traditional IABP (Intra-Aortic Balloon Pump) to evaluateNyokAssist^® pVADSafety and efficacy in HRPCI (High-Risk Percutaneous Coronary Intervention) patients. Preliminary clinical trial results show,NyokAssist^® pVADExcellent performance in high-risk PCI protection application scenariosThe device implantation was convenient and rapid, with minimal trauma, quick recovery, and no severe adverse events (including MACCE, severe vascular complications, infection, bleeding, etc.). All patients were successfully weaned off the machine and discharged after recovery.

With the continuous advancement of technology and the further expansion of clinical applications,NyokAssist^® pVADIt is expected to become an important device in the treatment of cardiovascular diseases, especially with broad application prospects in life support for patients undergoing minimally invasive interventions and high-risk cardiac surgeries.

Fully Magnetically Levitated Artificial Heart MoyoAssist(®) Extra-VAD

Exploring the Cutting-Edge Technology of Fully Magnetically Levitated Artificial Hearts

▼▼▼

MoyoAssist^® Extra-VADIt is the first domestically produced extracorporeal fully magnetically levitated artificial heart in China, developed by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology.Professor Dong Nianguo's TeamAn innovative product co-developed through collaborative innovation and joint research efforts with magAssist. This product utilizes full magnetic levitation technology to achieve zero-contact operation of the blood pump impeller.Directly avoid mechanical friction, significantly reduce blood damage, with advantages such as small size, light weight, and excellent blood compatibility, it can provide comprehensive circulatory support for patients with acute heart failure, especially for post-surgical low cardiac output, bridge to heart transplantation, acute cardiogenic shock, and biventricular failure.

MoyoAssist^®The clinical trial results of Extra-VAD show that it isExcellent performance in low shear stress and high blood compatibility, the force distribution within the pump maintains over 90% of the area below 50 Pa, ensuring the safety of blood flow inside the pump. The blood residence time in the secondary flow path is less than 0.5 seconds, preventing blood stagnation and reducing the risk of thrombosis. Additionally, the hydraulic design of the device can adapt to a wide range of application scenarios, and the test results suggestMoyoAssist^®Extra-VADDemonstrates higher hemocompatibility, not only significantly improving patient survival rates but also effectively reducing the risk of complications such as hemolysis and thrombosis.As a high-end life support device independently developed in China, MoyoAssist^® Extra-VAD was approved for marketing by the National Medical Products Administration (NMPA) in April this year, filling the gap in China's artificial heart field.

At the same time, magAssist set up a product booth at the event site, where experts and scholars from all over the world experienced the products "up close" and engaged in in-depth exchanges.

[MagAssist Product Booth Attracts Attendees to Visit]

Swipe up and down to view more photos

Platform-based Product Layout

Building an Integrated, Modular Life Support "Toolbox"

▼▼▼

magAssist's innovative product portfolio in the field of mechanical circulatory assist technology demonstrates its strong R&D capabilities and forward-thinking approach in life support technology. Currently, the company has successfully launched several innovative devices, initially building an integrated and modular life support platform, with a product line includingFully Magnetically Levitated Artificial Heart MoyoAssist^® Extra VAD, Extracorporeal Membrane Oxygenation System BreathMo^® ECMO, Minimally Invasive Interventional Artificial HeartNyokAssist^® pVAD, as well as platforms for pediatric and infant ECMO and warm-blood organ transport, etc.Initially completed the layout starting from heart failure and extending to multi-organ life support, while achieving multi-indication coverage for non-endpoint treatment of heart failure, multi-scenario coverage, and multi-age group coverage.

magAssist, with its innovative products, aims to create a flexible and diverse "life support toolbox" that can provide personalized and precise life support solutions based on the specific conditions and treatment needs of patients. This will address complex medical scenarios, helping to improve patients' chances of survival and quality of life.

Through the development and application of this series of cutting-edge technologies, magAssist has not only accelerated the progress of mechanical circulatory assist technology in China but also brought more efficient and reliable life support solutions to the global medical market. The innovative achievements of magAssist are providing new treatment options and hope for survival to patients worldwide.

At the closing of this year's ISMCS annual conference, ISMCS also announced an exciting piece of news: ISMCS 2026 will be held in China. Professor Xu Bolei from magAssist, the only Chinese member of the ISMCS Board of Directors, made significant contributions to securing the hosting rights for ISMCS 2026 in China. The venue for ISMCS 2026 is set to be Suzhou, China, with the tentative dates being October 22-24, 2026. This will be the first time that the ISMCS annual meeting is held in China since its inception, marking a recognition of China’s contributions in the field of mechanical circulatory support and foreshadowing an expanded role for China in this domain.

Further Reading

Heavyweight: Suzhou Successfully Bids for the International Society of Mechanical Circulatory Support Annual Meeting (ISMCS 2026)

TCT 2024 | Professor Ge Junbo's Team from Shanghai Zhongshan Hospital Shares Latest Progress on China's Self-Developed, World's Smallest Interventional Ventricular Assist System

The First Extra-VAD Standardized Training Course Successfully Held! Continuously Promoting the Standardized Training and System Construction of Extracorporeal Ventricular Assist Technology in China

magAssist MoyoAssist® Grand Launch! Intermediate-Term Mechanical Circulatory Support Forum and Extra-VAD Clinical Technology Transfer Achievements Release Successfully Held

Recognized by Both China and the U.S., Transforming the Innovation Trend of Such Devices | magAssist's Minimally Invasive Interventional Artificial Heart Approved as an Innovative Medical Device!

- END -

Disclaimer:

The content of this article is solely for the purpose of information transmission or industry exchange. No content should be regarded as advertising, nor does it represent any explicit or implied advertising, and it should not be considered as any promise of sale or sales purpose. For accurate information, the audience is advised to consult professional medical institutions.